Qinghua Wang

Dr. Qinghua Wang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
YWYahao Wang
Yahao Wang
YZYue Zhou
Yue Zhou
ZWZhihong Wang
Zhihong Wang
YNYunzhi Ni
Yunzhi Ni
GPGerald J Prud'HOmme
Gerald J Prud'HOmme
QWQinghua Wang
Qinghua Wang
Objective: New therapies are urgently needed for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). We conducted this systematic review and meta-analysis to evaluate the therapeutic effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on MASLD/MASH. Methods: We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH. The effects of GLP-1RAs on liver fat content (LFC) by imaging, liver histology, serum liver enzymes, and noninvasive fibrosis indexes [Fibrosis-4, nonalcoholic fatty liver disease fibrosis score, cytokeratin 18, procollagen III, and liver stiffness) were evaluated. Mean differences and risk ratios with 95% confidence intervals were pooled using a random-effect model. Results: Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included. Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%, with retatrutide displaying the most obvious treatment effects. GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation but nonsignificantly improved fibrosis, with the evidence for tirzepatide more robust than that for semaglutide and liraglutide. GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control. GLP-1RAs also significantly improved liver stiffness, with semaglutide displaying the most obvious treatment effect. No drug-related adverse effects involving the liver were observed. Conclusion: GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH.

5 February 2025 in Chinese Medical Journal
Verified
Journal Article
Open access
YZYing Zhao
Ying Zhao
JLJia Li
Jia Li
AMAnran Ma
Anran Ma
ZWZhihong Wang
Zhihong Wang
YNYunzhi Ni
Yunzhi Ni
QWQinghua Wang
Qinghua Wang
Background: Disruption of hepatic lipid homeostasis leads to excessive hepatic triglyceride accumulation and the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Autophagy, a critical process in liver lipid metabolism, is impaired in MASLD pathogenesis. Irisin, a skeletal muscle-driven myokine, regulates lipid metabolism, but its impact on hepatic lipid metabolism is not well understood. Here, we aimed to explore the role of irisin in hepatic steatosis and the underlying mechanisms involved. Methods: A high-fat diet (HFD)-induced MASLD mouse model was used, and the recombinant irisin protein, herein referred to as “Irisin”, was intraperitoneally administered for 4 weeks to evaluate the effects of irisin on hepatic lipid accumulation. Liver tissues were stained with Oil red O (ORO), and triglyceride (TG) and total cholesterol (TC) contents were measured in serum and liver homogenates. The expression of the autophagosome marker microtubule-associated protein 1 light chain 3 (LC3), the autophagy receptor protein sequestosome-1 (SQSTM1/p62), autophagy initiation complex unc-51-like kinase 1 (ULK1) and the lysosomal functional protein cathepsin B was measured via Western blotting, and the expression of the transcription factor EB (TFEB) was analyzed via immunofluorescence to explore autophagic changes. The effect of irisin on autophagic flux was further evaluated in palmitic acid-induced HepG2 cells by measuring autophagic degradation with chloroquine (CQ), and analyzing the colocalization of LC3 and lysosome-associated protein 1 (LAMP1). The possible mechanism was examined by measuring the expression of the autophagic sirtuin 3 (SIRT3) pathway and further validated using overexpression of SIRT3 with plasmid transfection or small interfering RNA (siRNA)-mediated knockdown. Student’s t -test was utilized for statistical analysis. Results: Irisin significantly reduces hepatic lipid accumulation in mice fed with HFD, accompanied by enhanced hepatocyte autophagy and upregulation of the SIRT3 pathway. In HepG2 cells, Irisin attenuated palmitic acid-induced lipid accumulation, which was partially dependent on SIRT3 levels. Mechanistically, Irisin treatment upregulated SIRT3 and phosphorylated AMP-activated protein kinase (AMPK), inhibited mammalian target of rapamycin (mTOR) activity, promoted TFEB nucleus translocation, increased cathepsin B expression, enhanced autophagic degradation, and alleviated hepatic steatosis. No significant changes in phosphorylation of ULK1 in the hepatocytes were observed. However, when siRNA was used to knock down SIRT3 , the changes of those protein were partially reversed, and hepatic steatosis was further exacerbated. Conclusions: Our findings highlight irisin as a potential therapeutic for hepatic steatosis by modulating autophagy and lipid metabolism, potentially providing a novel therapeutic target for the management of MASLD. Further research is needed to elucidate the underlying mechanisms and explore the potential clinical applications of this approach in the treatment of MASLD.

4 July 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
QCQiaoli Cui
Qiaoli Cui
QYQiwei Yang
Qiwei Yang
ZWZhihong Wang
Zhihong Wang
YWYun Wan
Yun Wan
DJDongdong Jiang
Dongdong Jiang
QWQinghua Wang
Qinghua Wang

5 June 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
QWQinghua Wang
Qinghua Wang
QCQiaoli Cui
Qiaoli Cui
YXYulong Xu
Yulong Xu
GPGerald J. Prud'HOmme
Gerald J. Prud'HOmme
YYYuanxun Yang
Yuanxun Yang
JLJuan Li
Juan Li

29 August 2022 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
ZWZhihong Wang
Zhihong Wang
LFLinling Fan
Linling Fan
YNYunzhi Ni
Yunzhi Ni
DWDi Wu
Di Wu
AMAnran Ma
Anran Ma
QWQinghua Wang
Qinghua Wang

21 November 2025 in Diabetologia
Verified
Journal Article
Closed access
PDF file
DZDaLong Zhu
DaLong Zhu
JMJianhua Ma
Jianhua Ma
WWWeimin Wang
Weimin Wang
BSBimin Shi
Bimin Shi
XDXiaolin Dong
Xiaolin Dong
QWQinghua Wang
Qinghua Wang